[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","commit":"28a6975696","date":"2026-09-10","author":"Jude Gomila","message":"Tone pass: solution and mechanism first; frightening figures behind a click","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"history","before":"[\n      { year: 2000, title: \"Molecular portraits define the basal-like subtype\", note: \"Perou and Sørlie's expression profiling separates basal-like from luminal breast cancers.\", refs: [\"rna-seq\"] },\n      { year: 2...","after":"[\n      { year: 2000, title: \"Molecular portraits define the basal-like subtype\", note: \"Perou and Sørlie's expression profiling separates basal-like from luminal breast cancers.\", refs: [\"rna-seq\"] },\n      { year: 2..."}]},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"burden","before":"\"About 10-15% of breast cancers, ~200,000 cases per year worldwide; more common in younger women, Black women, and BRCA1 carriers.\"","after":"\"TNBC accounts for about 10-15% of breast cancers, roughly 200,000 cases per year worldwide, and is more common in younger women, Black women, and BRCA1 carriers.\""}]},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","commit":"cebb34a709","date":"2026-09-08","author":"Jude Gomila","message":"Guideline mapping on every standard-of-care row; sourced biomarker prevalence for 59 targets; GuidelineChip, PrevalenceTable, CancerPrevalen","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"standardOfCare","before":"[\n      { setting: \"Stage I (T1a-b N0)\", approach: \"Surgery ± radiation; chemotherapy for ≥T1c; TIL-high tumours have >90% 5-year RFS even without chemotherapy (OPTimal, ETNA, TIL-CHOICE cohorts). De-escalation trials...","after":"[\n      { setting: \"Stage I (T1a-b N0)\", approach: \"Surgery ± radiation; chemotherapy for ≥T1c; TIL-high tumours have >90% 5-year RFS even without chemotherapy (OPTimal, ETNA, TIL-CHOICE cohorts). De-escalation trials..."}]}]